ストックスクリーナーアプリを入手
1.895
13.47%
-0.295
アフターアワーズ：
1.90
0.005
+0.26%
前日終値:
$2.19
開ける：
$2.175
24時間の取引高:
1.83M
Relative Volume:
1.05
時価総額：
$184.99M
収益：
$32.31M
当期純損益:
$-237.09M
株価収益率:
-0.658
EPS:
-2.88
ネットキャッシュフロー:
$-219.11M
1週間 パフォーマンス:
-13.07%
1か月 パフォーマンス:
+13.81%
6か月 パフォーマンス:
-31.34%
1年 パフォーマンス:
-7.56%
1日の値動き範囲:
$1.89
$2.175
1週間の範囲:
$1.89
$2.285
52週間の値動き範囲:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Compare EDIT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.895 | 213.78M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-28 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-16 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-13 | ダウングレード | Truist | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-11-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-04 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-05-09 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | アップグレード | Citigroup | Neutral → Buy |
| 2023-10-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | アップグレード | Stifel | Hold → Buy |
| 2023-06-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 開始されました | Citigroup | Neutral |
| 2022-12-06 | 再開されました | Credit Suisse | Neutral |
| 2022-11-18 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 開始されました | BofA Securities | Neutral |
| 2021-10-19 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-24 | 開始されました | Stifel | Hold |
| 2021-09-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-08-09 | アップグレード | Truist | Hold → Buy |
| 2021-08-05 | アップグレード | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 開始されました | Goldman | Sell |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-26 | ダウングレード | Truist | Buy → Hold |
| 2021-01-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 開始されました | Robert W. Baird | Underperform |
| 2020-06-18 | 再開されました | SunTrust | Buy |
| 2020-02-21 | 開始されました | Wells Fargo | Equal Weight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-10 | 開始されました | Guggenheim | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Outperform |
| 2018-05-15 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-02-13 | 開始されました | CLSA | Underperform |
| 2018-01-23 | アップグレード | SunTrust | Hold → Buy |
| 2017-07-14 | 開始されました | SunTrust | Hold |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-10 | アップグレード | Jefferies | Hold → Buy |
| 2016-06-02 | 開始されました | Jefferies | Hold |
| 2016-02-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-29 | 開始されました | JP Morgan | Neutral |
| 2016-02-29 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine SVP Parison sells $957 in stock By Investing.com - Investing.com Australia
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Editas Medicine at TD Cowen: Strategic Focus on In Vivo CRISPR - Investing.com Canada
EDIT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Editas Medicine Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday - MarketBeat
Editas Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Gene editor Editas brings its story to Boston and Miami investors - Stock Titan
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Editas Medicine (NASDAQ:EDIT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Can Editas Medicine Inc. ride the EV waveQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
Market Moves: Whats the MACD signal for CARGWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Signal Recap: Can Editas Medicine Inc disrupt its industryBear Alert & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Movers: Can Editas Medicine Inc. outperform in the next rallyEarnings Risk Report & Reliable Volume Spike Trade Alerts - mfd.ru
Why Editas Medicine Inc. (8EM) stock could be next leaderJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Editas Medicine’s Volatile Comeback: Can CRISPR Hype Outrun Clinical Risk? - AD HOC NEWS
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Analyst Downgrade: Can Editas Medicine Inc grow without external fundingMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Can Editas Medicine Inc. stock sustain revenue growth2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru
Can Editas Medicine Inc. disrupt its industryWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
Companies Like Editas Medicine (NASDAQ:EDIT) Could Be Quite Risky - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
Editas Medicine achieves significant LDL reduction with EDIT-401 therapy - Traders Union
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well - simplywall.st
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Street Watch: Is Editas Medicine Inc stock a falling knife or bargain buy2025 Major Catalysts & Daily Oversold Bounce Ideas - baoquankhu1.vn
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Hedge Fund Bets: Can Editas Medicine Inc disrupt its industry2025 Buyback Activity & Precise Trade Entry Recommendations - baoquankhu1.vn
Fed Watch: Can Editas Medicine Inc. maintain sales growthJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Recap Report: Can Editas Medicine Inc. stock surprise with earnings upsidePortfolio Risk Summary & Low Risk Investment Opportunities - Bộ Nội Vụ
Retail Surge: Is Editas Medicine Inc stock affected by interest rate hikesJuly 2025 Decliners & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Inflation Data: Will Editas Medicine Inc stock remain a Wall Street favoriteJuly 2025 Recap & Detailed Earnings Play Strategies - moha.gov.vn
Is Editas Medicine Inc. stock overvalued by current metricsQuarterly Risk Review & AI Powered Trade Plan Recommendations - ulpravda.ru
Can Editas Medicine Inc. stock surprise with earnings upsideQuarterly Market Summary & Free Safe Entry Trade Signal Reports - Улправда
Will Editas Medicine Inc. stock remain a Wall Street favoriteMarket Sentiment Review & AI Driven Price Predictions - Улправда
Is Editas Medicine Inc. stock in correction or buying zone2025 Growth vs Value & Reliable Entry Point Alerts - Улправда
Can Editas Medicine Inc. stock attract ESG capital inflowsWall Street Watch & Real-Time Buy Signal Notifications - ulpravda.ru
Is Editas Medicine Inc. stock affected by interest rate hikesShort Setup & Reliable Volume Spike Trade Alerts - Улправда
Is Editas Medicine Inc. stock ready for breakout2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - Улправда
Street Watch: Can Editas Medicine Inc. (8EM) stock expand revenue streams2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - Улправда
Aug Catalysts: Why Editas Medicine Inc. (8EM) stock could rally stronglyQuarterly Profit Summary & Free Verified High Yield Trade Plans - Улправда
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Alka Securities LimitedMarket Sentiment Shifts & Free Realize Exceptional Returns - earlytimes.in
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9%Should You Sell? - MarketBeat
Editas Medicine (EDIT) price target increased by 22.78% to 4.95 - MSN
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Editas Medicine Inc (EDIT) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):